Op0062 identification of Six Dermatomyositis Subgroups Using Principal Component Analysis-Based Cluster Analysis

Abstract

BackgroundDermatomyositis (DM) is a heterogeneous disease with a wide range of clinical manifestations. Bohan and Peter suggested four subtypes of DM: idiopathic DM, juvenile DM, DM associated with cancer, and DM associated with other connective tissue diseases. Different DM subtypes have distinct clinical manifestations, responses to therapy and prognoses.ObjectivesThe aim of the present study was to identify the clinical subtypes of DM by applying cluster analysis.MethodsWe retrospectively reviewed the medical records of 720 DM patients and selected 21 variables for analysis, including clinical characteristics, laboratory findings, and comorbidities. Principal component analysis (PCA) was first conducted to transform the 21 variables into independent principal components. Patient classification was then performed using cluster analysis based on the PCA-transformed data. The relationships among the clinical variables were also assessed.ResultsWe transformed the 21 clinical variables into 9 independent principal components by PCA and identified 6 distinct subgroups. Cluster A was composed of two sub-clusters of patients with classical or moderate DM. Cluster-B patients were older and had malignancies. Cluster C was characterized by interstitial lung disease (ILD), skin ulcer, and minimal muscle involvement. Cluster D included patients with prominent lung, muscle, and skin involvement. Cluster E contained DM patients with other connective tissue diseases. Cluster F included all patients with myocarditis and prominent myositis and ILD. We found significant differences in treatment across the six clusters, with clusters C, D, and E being more likely to receive aggressive immunosuppressive therapy.ConclusionWe applied cluster analysis to a large group of DM patients and identified six clinical subgroups, underscoring the need for better phenotypic characterization to help develop individualized treatments and improve prognosis.References[1] Bohan, A. and J.B. Peter, Polymyositis and dermatomyositis (first of two parts). N Engl J Med, 1975. 292(7): p. 344-7.[2] Bohan, A. and J.B. Peter, Polymyositis and dermatomyositis (second of two parts). N Engl J Med, 1975. 292(8): p. 403-7.[3] Marie, I., Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep, 2012. 14(3): p. 275-85.[4] Callen, J.P., Dermatomyositis. The Lancet, 2000. 355(9197): p. 53-57.Fig. 1Fig. 2Disclosure of InterestsNone declared